Expression of CXCL12-CXCR4/CXCR7 chemokines in splenic fibrosis of cirrhotic spleen and its therapeutic significance

INTRODUCTION: To investigate the expression and treatment of chemokine CXCL12 and its receptor CXCR4/CXCR7. METHODS: The liver cirrhosis hypersplenism model of rats was made with CCL4, and then was detected by immunohistochemistry, Western blot and qRT-PCR. RESULTS: The area of spleen fibrosis in th...

Descripción completa

Detalles Bibliográficos
Autores principales: Lv, Yunfu, Li, Yejuan, Han, XiaoYu, Liu, Ning, Zeng, Min
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Termedia Publishing House 2023
Materias:
Research Letter
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10507761/
https://www.ncbi.nlm.nih.gov/pubmed/37732054
http://dx.doi.org/10.5114/aoms/170910
Descripción
Sumario:INTRODUCTION: To investigate the expression and treatment of chemokine CXCL12 and its receptor CXCR4/CXCR7. METHODS: The liver cirrhosis hypersplenism model of rats was made with CCL4, and then was detected by immunohistochemistry, Western blot and qRT-PCR. RESULTS: The area of spleen fibrosis in the model group was significantly larger than that in the control group (p < 0.01), and the expression of CXCL12, CXCR4 and CXCR7 in the model group was significantly higher than that in the control group (p < 0.01). CONCLUSIONS: CXCL12-CXCR4/CXCR7 is abnormally high in splenic fibrosis, and blocking its high expression can slow down the occurrence of hypersplenism.

Ejemplares similares